Relmada Therapeutics
RLMD5.2000.39% ( +0.020 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Relmada Therapeutics(RLMD) predict that the EBIT is -19.46 M (-6.82%), Beat estimate;the EPS is -0.22 (+62.07%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.02B6.82%
-0.02B9.66%
+0.00B2.84%
EPSMiss expectations
-0.2262.07%
-0.19566.38%
-0.02504.31%
Upcoming earnings report - FY2026 Q2 Earning Release
Available dateAug 6, 2026
Estimate Revenue0
Estimate EBIT-20.49 M
Estimate EPS-0.198
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf